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Abstract
Background: The dose-dependent anti-inflammatory effects of a recent fixed combination of extrafine
beclomethasone dipropionate/formoterol (BDP/F) were investigated using non-invasive markers of inflammation,
exhaled nitric oxide (NO) and adenosine monophosphate (AMP) provocative challenge. The aim was to assess the
onset of the anti-inflammatory action of low and high doses and evaluate the suitability of non-invasive
assessments to demonstrate dose response.
Methods: Steroid naïve adult out-patients with mild asthma, sensitive to AMP with baseline exhaled NO > 25 parts
per billion entered a double-blind, placebo-controlled, 3-way, cross-over study. Patients were randomised to low
dose (1 actuation) or high dose (4 actuations) extrafine BDP/F 100/6 μg, or placebo administered twice daily on
Days 1 and 2 and once in the morning on Day 3 of each period. Exhaled NO was measured pre-dose on Day 1,
then 2 and 4 hours post-administration on Day 3. The AMP challenge was performed 4 hours post-administration
on Day 3 and forced expiratory volume in 1 second (FEV1, L) was measured from 0 to 4 hours post-dose on Day 1.
Endpoints were NO at 2 and 4 hours, AMP challenge at 4 hours after the fifth dose on Day 3 and FEV1 area under
the curve from 0 to 4 h post-dose on Day 1. Analysis of covariance was performed for NO and FEV1 and analysis of
variance for AMP challenge.
Results: Eighteen patients were randomised and completed the study. Exhaled NO was significantly lower for both
doses of extrafine BDP/F versus placebo at 2 and 4 hours (high dose LS mean difference: -22.5 ppb, p < 0.0001
and -20.5 ppb, p < 0.0001; low dose: -14.1 ppb, p = 0.0006 and -12.1 ppb, p = 0.0043) with a significant dose
response (p = 0.0342 and p = 0.0423). Likewise, AMP challenge revealed statistically significant differences between
both doses of extrafine BDP/F and placebo (high dose LS mean difference: 4.8 mg/mL, p < 0.0001; low dose: 3.7
mg/mL, p < 0.0001), and a significant dose response (p = 0.0185). FEV1 was significantly improved versus placebo
for both doses (high dose LS mean difference: 0.2 L, p = 0.0001; low dose: 0.2 L p = 0.0001), but without a
significant dose response.
Conclusions: The fixed combination inhaler of extrafine BDP/F has early dose-dependent anti-inflammatory effects
with a rapid onset of bronchodilatation in mild asthmatic patients.
Trial Registration: ClinicalTrials.gov: NCT01343745
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Asthma is a chronic inflammatory disease of the whole
bronchial tree. Persistent inflammation of the airways
and increased bronchial reactivity has been recognised
even in mild asthma [1]. Current guidelines [2] suggest
a step-wise approach starting with inhaled corticoster-
oids (ICS), the mainstay of asthma therapy and the most
effective anti-inflammatory treatment available for per-
sistent asthma. Corticosteroids control airway inflamma-
tion and decrease bronchial hyperreactivity (BHR), thus
reducing asthma symptoms and improving lung function
[3]. Maximal clinical benefits from corticosteroids are
expected within weeks [4] but recent evidence suggests
that ICS can exert acute effects (within hours) on air-
ways inflammation and BHR [5-7].
There are, however, systemic side-effects at high doses
of ICS [8] and, in patients uncontrolled on a medium
doses of ICS, addition of an inhaled long-acting b2-ago-
nist (LABA) is the preferred therapy. These two classes
of drugs address complementary aspects of the patho-
physiology of asthma in terms of anti-inflammatory and
bronchodilating effects that neither class is able to
achieve alone [9]. On addition of a LABA, improve-
ments are seen in symptom scores and lung function
with a decrease in the number of exacerbations. The use
of a LABA with an ICS achieves clinical control in more
patients at a lower dose of the ICS than if the ICS were
used alone [10,11].
A fixed combination of beclomethasone dipropionate
(BDP) and formoterol (F) (Foster
®, Chiesi Farmaceutici),
delivered via a hydrofluoroalkane (HFA), pressurised
metered dose inhaler (pMDI), is characterised by an
extrafine particle formulation. This extrafine particle for-
mulation ensures uniform delivery of the two active
drugs to large and small airways, therefore treatment of
inflammation and bronchoconstriction is expected
throughout the whole bronchial tree [12].
The accurate assessment of the effect of treatment on
airways inflammation in asthma is important for suc-
cessful clinical management of the disease. There is a
growing interest in non-invasive markers of airways
inflammation, e.g. exhaled nitric oxide (NO) which
could be used in addition to traditional methods, such
as lung function tests and symptom scores, to monitor
early deterioration of lung function. Raised levels of
fractional exhaled nitric oxide (FENO) are associated
with inflammation in asthma, are responsive to suppres-
sion by corticosteroids and there is also evidence of its
association with asthma severity. This makes exhaled
NO a sensitive and practical surrogate marker to moni-
tor ICS treatment effect [13-15].
Bronchial hyperreactivity is present in virtually all
patients with asthma and is an indirect marker of airway
inflammation. A bronchoconstrictor stimulus to mea-
sure BHR is adenosine monophosphate (AMP) which
acts via release of histamine and other mediators from
mast cells. The concentration of AMP causing the
forced expiratory volume in 1 second (FEV1) to decrease
by 20% (AMP PC20) may be used as a non-invasive mar-
ker of airways inflammation and bronchoprotective
effects on AMP have been detected with both ICS and
LABA [16,17].
The FEV1 is a lung function parameter which is com-
monly used for monitoring the level of airways obstruc-
tion and an improvement in FEV1 after treatment with
b-agonists is well documented [18].
There is limited literature available on acute effects of
ICS treatment on surrogate markers of inflammation.
The models used so far have sometimes failed to show
dose-response effects and have never been tested in
ICS/LABA fixed combinations, whose use in asthma
management is continuously increasing. The objective of
this exploratory study was to assess the onset of the
anti-inflammatory action of a fixed combination of
extrafine BDP/F at increasing doses (low dose: 100/6 μg,
1 actuation; high dose: 100/6 μg, 4 actuations) and also
to evaluate the suitability of non-invasive assessments
(FENO,A M PP C 20 and FEV1) to demonstrate a dose
response. AMP challenge has proved to be a useful mar-
ker of corticosteroid anti-inflammatory activity but it is
known to be influenced also by the LABA component.
For this reason, we included also measurement of FENO
levels, which are specifically affected by ICS only, in
order to discriminate the contribution of the two com-
ponents of the fixed combination.
Methods
Study subjects
Patients were aged 18 to 50 years with clinical evidence
of asthma (associated with either demonstration of ≥
12% reversibility and 200 mL improvement of FEV1
using a standard dose of salbutamol within 30 minutes,
or historical BHR to methacholine, within 12 months of
the screening visit). They had to be steroid naïve (i.e.,
patients should have never taken steroid medications
before) with FEV1 > 70% of predicted value and at least
2.0 L at screening. Intake of any anti-asthmatic drug
had to be stopped before the study entry, with the
exception of inhaled salbutamol as rescue medication,
which was allowed during the study but for the 8 h
prior to lung function measurements. Patient’sa s t h m a
had to be stable, without experiencing any respiratory
tract infection or any exacerbation requiring treatment
with oral steroid in the 4 weeks prior to the study entry.
Patients were non-smokerso re x - s m o k e r s( <5p a c k -
years). Patients had a body mass index (BMI) between
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2. Patients had to be sensitive to AMP
(PC20 after the AMP challenge test at screening ≤ 20
mg/mL) and have baseline FENO levels > 25 parts per
billion (ppb). Patients with history of cystic fibrosis or
bronchiectasis or alpha-1 antitrypsin deficiency or any
other clinically significant lung disease, including COPD,
were not included in the study. The study was carried
out in accordance with the Declaration of Helsinki, the
ICH Harmonised Tripartite Guideline for Good Clinical
Practice (GCP), and with applicable regulatory require-
ments. The study protocol was approved by an indepen-
dent ethics committee (the St Thomas’ Research Ethics
Committee London, United Kingdom).
Study design
This was a single centre study of randomised, double-
blind, double-dummy, placebo controlled, 3-way multi-
ple dose, cross-over design (Figure 1). Treatments were
randomly assigned (3 treatments, 6 sequences) and the
randomisation list was not accessible to patients, investi-
gators, monitors or employees of the clinical site and
the sponsor’s clinical team, unless in case of emergency.
Patients were recruited from the clinical site database
and by advertising. After screening, eligible patients
entered the study, which comprised three 3-day treat-
ment periods each separated by a 10-day wash-out per-
iod. The period of wash-out was chosen according to
available literature [5,19] and it is in line with the phar-
macokinetic properties of BDP, showing an elimination
half-life of about 3 hours for the active metabolite 17-
BMP [20]. The 3 treatments administered were:
￿ low dose extrafine BDP/F (Foster
®; Chiesi Farma-
ceutici): 100/6 μg, 1 actuation
￿ high dose extrafine BDP/F: 100/6 μg, 4 actuations
￿ placebo pMDI.
The order in which each patient received the treat-
ments was randomised. Study treatments were adminis-
tered twice daily on Days 1 and 2, and once, in the
morning, on Day 3 (a total of 5 doses). Before taking
the study medication, patients were trained to the use of
the pMDI inhaler with Vitalograph
® Aerosol inhalation
monitor. No spacer was used for drug administration
during the study.
The efficacy endpoints were:
￿ FENO levels at 2 and 4 hours after the fifth dose on
Day 3 of each study period
￿ AMP PC20 at 4 hours after the fifth dose on Day 3
of each study period
￿ normalised by time-area under the curve between
0 and 4 hours (AUC0-4h) after the morning adminis-
tration FEV1 measured on Day 1 of each study
period.
Measurement of FENO
Standardised FENO measurements were performed using
the NIOX
® (Aerocrine, Solna, Sweden) analyser. NO
was measured at 50 mL/s expiratory rate, according to
standard procedures [21,22]. The average of two accep-
table values was considered for the statistical analysis.
FENO measurements were performed at screening and
during each treatment period on Day 1 pre-dose, and 2
and 4 hours post-administration on Day 3. In case of
concomitant assessments, these measurements were
conducted immediately before the AMP challenge test.
AMP challenge test
The AMP challenge test was performed at screening and
on Day 3 of each treatment period 4 hours post-admin-
istration, according to a standardized challenge protocol
as previously described [23]. The highest of 3 FEV1
recordings taken before administration of the diluent
was used as the pre-saline baseline. The challenge was
n o tc a r r i e do u ti fF E V 1 was < 60% predicted or the
patient manifested significant asthma symptoms of
wheeze, chest tightness or cough. Patients inhaled 0.9%
saline, nebulised from a breath-activated dosimeter of
known output. The higher of two measurements taken
after inhalation of saline was used as the post-diluent
FEV1 to calculate the PC20 value. Patients then inhaled
doubling increments of AMP until a ≥ 20% fall in FEV1
from the post-saline value was achieved or the maxi-
mum concentration had been given. If the highest FEV1
between the two duplicates was < 20% below the post-
saline FEV1 reference, patients progressed to the next
highest concentration of AMP. Doubling concentrations
of AMP ranging from 0.16 to 640 mg/mL were used.
Measurement of FEV1
At screening, FEV1 was measured before and after
administration of salbutamol for the reversibility test.
During each treatment period, FEV1 area under the
curve (AUC) was calculated from 0 to 4 h post-dose on
Day 1 by measuring FEV1 pre-dose and 0.5, 1, 2 and 4
Figure 1 Study design.
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acic Society/European Respiratory Society standards
[24]. For Caucasians of non-European descent and non-
Caucasians, predicted values for FEV1 and forced vital
capacity (FVC) were to be adjusted for race as per the
European Coal and Steel Community (ECSC) guidelines
[25]. Values were corrected for BTPS conditions (satu-
rated with water vapour at body temperature [37°C] and
at the ambient barometric pressure). The rescue medica-
tion (salbutamol) was to be withheld for at least 8 hours
prior to administration of each dose of study
medication.
Safety assessments
Evaluation of the safety profile included collection and
monitoring of any adverse events (AEs) throughout the
study. Vital signs (heart rate and blood pressure) were
measured at screening and in each treatment period
before and after drug administration and routine clinical
laboratory assessments were made at screening and at
the end of the study.
Statistical analysis
Due to the exploratory nature of this study, no formal
sample size calculation was made. Efficacy data were
analysed for the intention-to-treat (ITT) population as
well as the per-protocol (PP) population. The ITT popu-
lation included all randomised patients who received at
l e a s to n ei n h a l a t i o no fs t u d yd r u ga n dh a da tl e a s to n e
post-baseline efficacy evaluation. The PP population
included all patients from the ITT population without
any major protocol violation (i.e. wrong inclusion, poor
compliance, intake of forbidden medication, etc). Effi-
cacy data from the ITT and PP populations were com-
parable. Therefore, only the results from the ITT
population are reported in the current paper. Safety was
assessed in all randomised patients who received at least
one inhalation of study medication.
Comparison between treatments for FENO and FEV1
AUC(0-4h) was carried out using an analysis of covar-
iance (ANCOVA) for a cross-over design with patient
(sequence and patient within sequence), period and
treatment as factors of the model and pre-dose values
on each treatment period as covariate.
The following rule was applied for PC20 calculation
when patients did not reach a 20% fall in FEV1: an AMP
concentration of 640 mg/mL was used for patients with
10% or greater FEV1 fall; an AMP concentration of 1280
mg/mL (twice the maximum concentration level of
AMP administered) was used for patients with an FEV1
fall less than 10%. A logarithmic transformation using
base 2 (Log2) was applied before analysis for PC20 (dou-
bling doses scale). Comparison between treatments for
PC20 was carried out using an analysis of variance
(ANOVA) for a cross-over design with patient
(sequence and patient within sequence), period and
treatment as factors of the model.
For each comparison, the least square (LS) mean, pair-
wise treatment effect, the 95% confidence interval (CI)
and the probabilities (p-values) were shown.
Results
Of 36 patients screened, 18 (10 males and 8 females)
were randomised, received study medication and all
completed the study. All patients gave their written
informed consent before any study related procedure.
Randomised patients had a median age of 28.5 years
(range: 19-46 years). The other demographic characteris-
tics and baseline data for the study population are pro-
vided in Table 1. Patients had a history of mild asthma
for a median period of 21 years (range: 4-46 years) and
were steroid naïve. Seventeen out of 18 randomised
patients were taking salbutamol as rescue medication
for asthma before the study entry. At screening, median
FEV1 was 3.4 L (98.5% of predicted) and median FVC
was 4.4 L (111.0% of predicted). The efficacy results for
the endpoints assessed in this study (FENO,A M PP C 20,
and FEV1) are presented in Table 2 and the statistical
comparisons are shown in Table 3.
FENO
The FENO at 2 hours post-treatment on Day 3 was sig-
nificantly lower after both doses of extrafine BDP/F
compared with placebo (high dose comparison LS mean
difference: -22.5 ppb, p < 0.0001; low dose comparison:
-14.1 ppb, p = 0.0006, respectively) (Table 3). The
results were similar at 4 hours post-treatment on Day 3
with FENO significantly lower after both doses of extra-
fine BDP/F compared with placebo (high dose compari-
son: -20.5 ppb, p < 0.0001; low dose comparison: -12.1
ppb, p = 0.0043, respectively) (Table 3). At both time
points a significant dose response was confirmed (high
vs low dose comparison: -8.4 ppb; p = 0.0342 and p =
0.0423 at 2 and 4 hours, respectively). Figure 2 shows
Table 1 Patients’ characteristics and baseline data.
Characteristic Mean ± SD Median (Range)
Age (years) 30.6 ± 9.2 28.5 (19-46)
FEV1 (L) 3.4 ± 0.7 3.4 (2.2-4.5)
% FEV1 predicted 94.9 ± 10.5 98.5 (71-111)
FVC (L) 4.4 ± 1.1 4.4 (2.8-6.2)
% FVC predicted 105.3 ± 13.2 111.0 (65-118)
FENO (ppb) 72.4 ± 27.1 82 (27-120)
AMP PC20 (mg/mL) 6.5 ± 6.0 4.5 (0.4-19.3)
SD = standard deviation; FEV1 = forced expiratory volume in one second; FVC
= forced vital capacity; FENO = Fractional exhaled nitric oxide; AMP PC20 =
AMP challenge provocative concentration causing a 20% fall in FEV1
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ment group.
PC20 AMP
The AMP PC20 on Day 3 was significantly higher after
both doses of BDP/F compared with placebo (high dose
comparison LS mean difference: 4.8, p < 0.0001; low
dose comparison: 3.7, p < 0.0001) (Table 3). A
significant dose response was confirmed between high
and low dose (p = 0.0185) with a difference of 1.0 in
AMP PC20 on doubling the dose concentration. Figure 3
shows the LS mean AMP PC20 for each treatment
group. Few patients showed FEV1 values < 60% pre-
dicted after the last administered provocative concentra-
t i o no fA M P ,b u tt h e yd i dn o tm a n i f e s ta n ya s t h m a
symptom.
FEV1
The AUC0-4h using FEV1 (L) on Day 1 was significantly
higher after both doses of BDP/F compared with pla-
cebo (high dose comparison LS mean difference: 0.2, p
= 0.0001; low dose comparison: 0.2, p = 0.0001) (Table
3). No significant dose response was confirmed. Figure 4
shows the LS mean FEV1 over time on Day 1 for each
treatment group.
Table 2 Efficacy endpoints: FENO,P C 20 AMP, and FEV1.
FENO (ppb) - Day 3, 4 hours LS Mean 95% CI
High dose 50.5 43.8, 57.3
Low dose 58.9 52.2, 65.7
Placebo 71.1 64.4, 77.8
FENO (ppb) - Day 3, 2 hours LS Mean 95% CI
High dose 51.8 44.5, 59.2
Low dose 60.2 53.0, 67.5
Placebo 74.4 67.2, 81.5
AMP PC20 (mg/mL) - Day 3, 4 hours Log2 LS Mean Log2 95% CI
High dose 7.1 5.9, 8.2
Low dose 6.0 4.9, 7.1
Placebo 2.3 1.2, 3.4
FEV1 (L) - AUC 0-4 h Day 1 LS Mean 95% CI
High dose 3.6 3.5, 3.6
Low dose 3.6 3.5, 3.6
Placebo 3.4 3.3, 3.4
LS Mean = least squares mean; CI = confidence interval; FENO = Fractional
exhaled nitric oxide; AMP PC20 = AMP challenge provocative concentration
causing a 20% fall in FEV1;F E V 1 = forced expiratory volume in one second.
Table 3 Statistical comparisons of efficacy endpoints.
FENO (ppb) - Day 3, 4 hours LS Mean 95% CI P-value
High dose - placebo -20.5 -28.5, -12.6 < 0.0001
Low dose - placebo -12.1 -20.1, -4.1 0.0043
High dose - low dose -8.4 -16.6, -0.3 0.0423
FENO (ppb) - Day 3, 2 hours LS Mean 95% CI P-value
High dose - placebo -22.5 -30.1, -15.0 < 0.0001
Low dose - placebo -14.1 -21.7, -6.6 0.0006
High dose - low dose -8.4 -16.2, -0.7 0.0342







High dose - placebo 4.8 3.9, 5.6 < 0.0001
Low dose - placebo 3.7 2.8, 4.6 < 0.0001
High dose - low dose 1.0 0.2, 1.9 0.0185
FEV1 (L) - AUC 0-4 h Day 1 LS Mean 95% CI P-value
High dose - placebo 0.2 0.1, 0.3 0.0001
Low dose - placebo 0.2 0.1, 0.3 0.0001
High dose - low dose 0.0 -0.1, 0.1 0.9832
LS Mean = least squares mean; CI = confidence interval; FENO = Fractional
exhaled nitric oxide; AMP PC20 = AMP challenge provocative concentration
causing a 20% fall in FEV1;F E V 1 = forced expiratory volume in one second.
Figure 2 FENO levels at 4 hours post-administration after 3
days of treatment with extrafine BDP/F low dose (100/6 μg, 1
actuation), high dose (100/6 μg, 4 actuations), or placebo.
Columns and bars represent LS mean and 95% CI.
Figure 3 AMP PC20 at 4 hours post-administration after 3 days
of treatment with extrafine BDP/F low dose (100/6 μg, 1
actuation), high dose (100/6 μg, 4 actuations), or placebo.
Columns and bars represent LS mean and 95% CI.
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The rate of adverse events (AEs) reporting was similar
for each treatment. Adverse events were reported by 7
patients (39%) during placebo treatment, 7 (39%) during
low dose extrafine BDP/F treatment, and 8 (44%) during
high dose extrafine BDP/F treatment. Most AEs were
recorded as not related to study medication. There were
no deaths, serious AEs or withdrawals due to AEs.
There were also no clinically significant laboratory
results and no clinically significant changes in vital
signs.
Discussion
Several studies have reported that ICS can exert a rapid
anti-inflammatory activity within few days from the
beginning of treatment [5-7]. Results have shown rapid
improvement of surrogate markers of inflammation,
such as FENO and AMP PC20, but these effects were not
always dose-dependent [26,7,6]. To our knowledge, this
is the first study assessing the acute anti-inflammatory
activity of an ICS/LABA fixed combination on two dif-
ferent surrogate endpoints, i.e. FENO and PC20 to AMP
challenge, and at two different dose levels. In addition
to confirming previous results on acute effects of ICS,
these findings provide evidence of a useful model to be
used for comparative studies. Reference guidelines
require equivalence between inhalation drugs to be stu-
died by comparison of at least two different doses and
after 4 weeks of treatment [27]. With this study, we
have shown that significant effects can be already
detected after 3 days of treatment with an ICS/LABA
fixed combination and that the model is dose sensitive.
Aalbers et al. [19] conducted a placebo-controlled
study comparing one single dose of budesonide/formo-
terol fixed combination against formoterol alone and
against salbutamol alone. The study measured only
changes in airways responsiveness to AMP challenge,
which is a useful marker of corticosteroid anti-inflam-
matory activity but also of the effects of the LABA com-
ponent [16,17]. Greater effects were seen with the fixed
combination at 3 and 7 hours after inhalation compared
with either b2-agonists alone, supporting an additive
effect of ICS in protecting against AMP-induced
bronchoconstriction. In contrast to the study of Aalbers
et al. [19], our study also included measurement of a
surrogate marker specifically affected by ICS only, i.e.
FENO levels, in order to distinguish the contribution of
the ICS from that of the LABA component in determin-
ing the acute response to BDP/F.
The efficacy parameters all demonstrated statistically
significant differences between both doses of BDP/F
(BDP/F 100/6 μg, 1 actuation vs 4 actuations) and pla-
cebo. In addition, FENO a t2a n d4h o u r so nD a y3a n d
PC20 after AMP tests demonstrated statistically signifi-
cant differences between the 2 dose levels of study drug.
FENO reflects eosinophilic airways inflammation and
various studies have provided sufficient data to justify
the use of FENO to identify and monitor steroid
response as well as steroid requirements in the diagnosis
and management of asthma. Kharitonov and Barnes [13]
measured FENO levels in 28 patients with mild asthma
who were administered 400 μgb u d e s o n i d e ,1 0 0μg
budesonide or placebo once daily for 3 weeks followed
by 1 week without treatment in a parallel group study.
A dose-dependent speed of onset and cessation of
action of budesonide was seen on FENO and asthma
symptoms. However, no changes compared with base-
line were seen early at 3 and 6 hours after single dose;
changes were noted only from Day 3 and these were
dose-dependent. Similarly, our experimental model, uti-
lising several outcome measures and early post-treat-
ment observations, enabled us to see significant acute
dose-response reduction of FENO after 3 days of treat-
ment with an extrafine ICS/LABA fixed combination.
Erin et al. [7] investigated the rapid effect of inhaled
ciclesonide on FENO levels in 21 mild asthmatics admi-
nistered ciclesonide 320 μg once daily, ciclesonide 640
μg twice daily or placebo for 7 days in a double blind
cross-over study. Exhaled NO was assessed on Days 1, 3
and 7 after inhalation of study drug. Both ciclesonide
320 μg once daily and 640 μg twice daily produced sig-
nificantly reduced exhaled NO levels from Day 3 com-
pared with placebo but a dose-dependent response was
not seen. Ciclesonide is known to be clinically effective
at doses lower than those used in the study reported, so
the doses administered in this study may have been too
high to detect any dose-dependent response. The study
by Erin et al. [7] also investigated the effects of cicleso-
nide on AMP PC20 challenge test. Both doses of cicleso-
nide significantly reduced airways responsiveness
Figure 4 Mean FEV1 on the first day of treatment with
extrafine BDP/F low dose (100/6 μg, 1 actuation), high dose
(100/6 μg, 4 actuations), or placebo.
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dent response was not seen. Another study [28]
reported dose-related improvement of PC20 to AMP
challenge in 29 patients with mild to moderate allergic
asthma treated with ciclesonide 100 μg, 400 μga n d
1600 μg daily. However, in this study patients under-
went a longer treatment of 14 days and no measurement
was taken to assess short-term changes in AMP PC20.
The study by Taylor et al. [23] also observed a signifi-
cant reduction in the percentage of eosinophils in
induced sputum for 400 μg and 1600 μg ciclesonide
daily but this was not dose-dependent.
Ketchell et al [6] investig a t e dt h er a p i de f f e c to f
inhaled fluticasone propionate therapy (100, 250, or
1000 μg) on airway responsiveness in 3 consecutive
cross-over studies in steroid naïve subjects with mild
asthma. The results showed that fluticasone significantly
reduced airway responsiveness to AMP in comparison
with placebo after 3 and 7 inhalations and a trend
towards a greater effect with a higher dose was
observed, although the difference did not achieve statis-
tical significance. In these studies, the AMP challenge
test was performed 2 hours after inhalation differently
from other studies where AMP PC20 was measured at 4
hours. The time interval between drug administration
and AMP challenges may have been too short to detect
any significant dose-related change.
There is limited literature available on the acute
effects of ICS treatment on surrogate markers of inflam-
mation in asthma. These studies reported significant
improvement of FENO levels and BHR, but in most
cases they did not demonstrate the dose-dependent nat-
ure of the response to steroid treatment.
Our study design was a 3-way cross-over study with 3
days of treatment and 10 days washout. This model
allowed discrimination of rapid and dose-related differ-
ences on two different markers of inflammation after 5
inhalations of study drug. By combining the use of AMP
PC20, which is an index of the effects of ICS and LABA,
and FENO, which is affected by ICS only, we were able
to show that the ICS component of extrafine BDP/F
fixed combination can exert a rapid anti-inflammatory
activity. The dose response observed for FENO is driven
by the ICS component of the fixed combination, as it is
well known that formoterol monotherapy has no effects
on exhaled NO. With regard to the dose response
observed for AMP PC20, it is recognized that formoterol
exhibited antagonism against AMP challenge to a lesser
degree than ICS [29]. However, it is our opinion that
dose response observed for AMP PC20 is likely due to
both components of the fixed combination. No differ-
ence was found in FEV1 values between low and high
dose BDP/F. This was to be expected because the study
involved steroid naïve patients in order to avoid
confounding factors that could have masked the effect
of the ICS in the study drug. The treatment was well
tolerated in this study population.
The limitations of our study are related to the small
s a m p l es i z ea n dt ot h ep o s s i b l eo v e r l a p p i n ge f f e c t so f
the ICS and LABA components. Due to the explora-
tory nature of the study it was not possible to make a
formal sample size calculation. However, despite the
reduced number of enrolled patients, we were able to
identify significant improvement of airway inflamma-
tion and to detect a dose-response effect. As far as the
AMP challenge test is concerned, it is known that this
parameter is not specific for ICS only but can be
affected also by the LABA included in the fixed combi-
nation. To overcome this limitation, we measured also
the levels FENO, which is specifically affected by ICS
only.
Conclusions
In conclusion, we demonstrated that extrafine BDP/F
(100/6 μg per actuation) has rapid anti-inflammatory
effects and produces a prompt early bronchodilator
effect in patients with mild asthma. Also, that surrogate
markers of inflammation such as FENO and AMP PC20
are useful to demonstrate early dose-dependent effects
of treatment.
List of abbreviations
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AMP causing a 20% fall in FEV1; BDP/F beclomethasone dipropionate/
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expiratory volume in 1 second; FVC: forced vital capacity; HFA:
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